Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3499073 | 0.88 | POLB (0.33) | SYKTSHRHTR2CSLC6A4POLB | |
| SCHEMBL14632793 | 0.78 | TSHR (0.50) | TSHRPOLB | |
| SCHEMBL6167343 | 0.77 | MAP2K4 (0.32) | FAAHMAP2K4 | |
| SCHEMBL3501462 | 0.77 | NR1H2 (0.36) | MAP2K4SYK | |
| SCHEMBL28442438 | 0.77 | MEN1 (0.37) | FAAH | |
| SCHEMBL2961171 | 0.76 | FAAH (0.40) | FAAHELANEMAP2K4BCHETSHR | |
| SCHEMBL3499314 | 0.76 | MMP13 (0.37) | — | |
| SCHEMBL5400751 | 0.75 | FAAH (0.39) | FAAHELANEMAP2K4BCHETSHR | |
| SCHEMBL13024386 | 0.75 | FAAH (0.39) | FAAHELANEMAP2K4BCHETSHR | |
| SCHEMBL161429 | 0.75 | FAAH (0.39) | FAAHELANEMAP2K4BCHETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144793-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS | AC IMMUNE SA (CH) | 2010-06-10 | — | — | US | disclosed |
| US-20100144793-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS | AC IMMUNE SA (CH) | 2010-06-10 | — | — | US | disclosed |
| US-20100144793-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS | AC IMMUNE SA (CH) | 2010-06-10 | — | — | US | disclosed |
| EP-2121619-A2 | COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS | AC Immune S.A. (CH) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008061796-A2 | COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS | AC IMMUNE SA (CH) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008061796-A2 | COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS | AC IMMUNE SA (CH) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144793-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS | APP, BACE1, APBA1 | FAAH 544/4885ELANE 373/4885MAP2K4 2629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.